Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ocoee, Florida Clinical Trials

A listing of Ocoee, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (42) clinical trials

A Study of the Effect of IW-1701 (Olinciguat) a Stimulator of Soluble Guanylate Cyclase (sGC) on Patients With Sickle Cell Disease (SCD)

The primary objective of the 1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW-1701 compared with placebo when administered daily for approximately 12 weeks to patients with stable SCD. Exploratory objectives include evaluation of pharmacokinetic (PK) as well as evaluation of the ...

Phase

6.78 miles

Learn More »

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

Phase

6.78 miles

Learn More »

The STRONG SCD study is being conducted to help advance research into an oral investigational drug for people with sickle cell disease (SCD). It is evaluating the investigational drug—compared to placebo (looks like the investigational drug but does not contain any active ingredient)—to understand how it affects people with SCD ...

Phase

6.78 miles

Learn More »

A Study To Assess Pharmacodynamics Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and ...

Phase

6.78 miles

Learn More »

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF 06700841 In Subjects With Moderate To Severe Crohn's Disease

The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed ...

Phase

7.19 miles

Learn More »

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

This is a non-randomized, Phase 2, 2-cohort, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with metastatic PD-L1+ NSCLC. Both first and second line subjects will be enrolled including: Cohort 1: Subjects with newly diagnosed, metastatic PD-L1+ (TPS 50%) NSCLC with no EGFR or ALK genomic tumor aberrations, ...

Phase

8.34 miles

Learn More »

Safety Study of Unlicensed Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. Therefore, the study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of ...

Phase

8.34 miles

Learn More »

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

8.34 miles

Learn More »

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

A phase 2, multicenter, multi-cohort, open-label study of pomalidomide in combination with low-dose dexamethasone or pomalidomide in combination with low-dose dexamethasone and daratumumab in subjects with relapsed or refractory multiple myeloma following lenalidomide based therapy in the first or second line setting. This trial will assess, Overall Response Rate (ORR), ...

Phase

8.34 miles

Learn More »

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

This open-label multicenter study will be conducted in 2 stages. Lead-in Phase: The first 6 patients treated will be evaluated to confirm the safety and feasibility of this regimen. After all 6 patients complete at least 4 weeks of treatment, and if no prohibitive toxicities are identified, continuous study treatment ...

Phase

8.34 miles

Learn More »